-+ 0.00%
-+ 0.00%
-+ 0.00%

Rein Therapeutics releases corporate presentation on LTI-03 idiopathic pulmonary fibrosis program

PUBT·08/19/2026 18:42:41
Listen to the news
Rein Therapeutics releases corporate presentation on LTI-03 idiopathic pulmonary fibrosis program
  • Rein Therapeutics highlighted lead inhaled peptide LTI-03 for idiopathic pulmonary fibrosis, now in Phase 2 with an interim readout expected in 2026.
  • Phase 1b met its primary endpoint; high-dose 5 mg twice daily was well tolerated with no identified safety issues.
  • Program showed biomarker shifts linked to lung health, including a 5% decrease in surfactant protein D over two weeks at 5 mg.
  • Management framed LTI-03 as a multi-pathway caveolin-1 scaffolding domain mimic with antifibrotic activity, alongside signals of epithelial cell support.
  • Pipeline update flagged LTI-01 for loculated pleural effusions as Phase 2b-ready, with development temporarily delayed to prioritize LTI-03.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.